Alcon Announces FDA Approval of TRYPTYR (Acoltremon Ophthalmic Solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Is the Peep Club heated eye wand the solution to dry eyes?

Screen overexposure left my eyes tired and sore, but Peep Club’s soothing wand has restored their twinkle

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

GENEVA--(BUSINESS WIRE)--May 28, 2025-

Alcon Announces FDA Approval of TRYPTRY Drops for Dry Eye

Photo courtesy of Alcon. Alcon has announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production.3 DED is a complex, multifactorial condition driven…

US FDA approves Alcon’s Tryptyr ophthalmic solution for Dry Eye Disease

Previously known as AR-15512, Tryptyr is a transient receptor potential melastatin 8 (TRPM8) receptor agonist that stimulates corneal sensory nerves to increase production of natural tears rapidly. It The post US FDA approves Alcon’s Tryptyr ophthalmic solution for Dry Eye Disease appeared first on Pharmaceutical Business review.

FDA Approves Acoltremon Ophthalmic Solution for Dry Eye Disease

The new approval is for a first-in-class TRPM8 receptor agonist to stimulate corneal sensory nerves to increase natural tear production.

FDA Approves Alcon’s Tryptyr for Dry Eye Disease

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S. market in the third quarter of 2025. International rollouts are expected to follow.